Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, James A.R., Wilkinson, David, Holmes, Clive, Steart, Phil, Markham, Hannah, Weller, Roy O.·2003·Nature Medicine
DOI 10.1038/nm840

Cited by (1,000)

Items 301–400 of 1,000

  1. The effect of insomnia on development of Alzheimer’s disease
    Shaghayegh Sadeghmousavi, Mahsa Eskian, Farzaneh Rahmani, Nima Rezaei · 2020 · Journal of Neuroinflammation
  2. Peripherally Administered Human Umbilical Cord Blood Cells Reduce Parenchymal and Vascular β -Amyloid Deposits in Alzheimer Mice
    William V. Nikolic, Huayan Hou, Terrence Town, Yuyan Zhu, Brian N. Giunta, Cyndy Davis Sanberg, Jin Zeng, Deyan Luo, Jared C. Ehrhart, Takashi Mori et al. · 2008 · Stem Cells and Development
  3. Autoantibodies against β‐amyloid are common in Alzheimer's disease and help control plaque burden
    Kellner, Alexander, Matschke, Jakob, Bernreuther, Christian, Moch, Holger, Ferrer, Isidro, Glatzel, Markus · 2009 · Annals of Neurology
  4. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease
    Lassmann, Hans · 2011 · Journal of Neural Transmission
  5. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial
    Davtyan, Hayk, Ghochikyan, Anahit, Petrushina, Irina, Hovakimyan, Armine, Davtyan, Arpine, Poghosyan, Anna, Marleau, Annette M., Movsesyan, Nina, Kiyatkin, Anatoly, Rasool, Suhail et al. · 2013 · The Journal of Neuroscience
  6. Physical activity and cognition in old age
    Nicola T. Lautenschlager, Osvaldo P. Almeida · 2006 · Current Opinion in Psychiatry
  7. Cerebral amyloid angiopathy: Pathogenesis and effects on the ageing and Alzheimer brain
    Roy O. Weller, James A. R. Nicoll · 2003 · Neurological Research
  8. Aβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
    Dickstein, Dara L., Biron, Kaan E., Ujiie, Maki, Pfeifer, Cheryl G., Jeffries, Andrew R., Jefferies, Wilfred A. · 2006 · The FASEB Journal
  9. Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
    Lacosta, Ana-María, Pascual-Lucas, María, Pesini, Pedro, Casabona, Diego, Pérez-Grijalba, Virginia, Marcos-Campos, Iván, Sarasa, Leticia, Canudas, Jesus, Badi, Hassnae, Monleón, Inmaculada et al. · 2018 · Alzheimer's Research & Therapy
  10. ADDLs and the signaling web that leads to Alzheimer’s disease
    Grant A. Krafft, William L. Klein · 2010 · Neuropharmacology
  11. Novel insights for the treatment of Alzheimer's disease
    Alexander Kurz, Robert Perneczky · 2010 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  12. Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
    Ghiam Yamin, Kenjiro Ono, Mohammed Inayathullah, David B. Teplow · 2008 · Current Pharmaceutical Design
  13. Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
    Anthony, Danielle Paige, Hegde, Manasa, Shetty, Shreya S., Rafic, Thasneema, Mutalik, Srinivas, Rao, B.S. Satish · 2021 · Life Sciences
  14. Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease
    Richard C. Dodel, Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang H. Oertel · 2010 · Drugs
  15. Molecular Basis of Catalytic Chamber-assisted Unfolding and Cleavage of Human Insulin by Human Insulin-degrading Enzyme
    Marika Manolopoulou, Qing Guo, E. Malito, Alexander B. Schilling, Wei‐Jen Tang · 2009 · Journal of Biological Chemistry
  16. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses
    Bryce Chackerian, Marisa Rangel, Zoe N. Hunter, David S. Peabody · 2006 · Vaccine
  17. Macrophages in Alzheimer’s disease: the blood-borne identity
    Gate, David, Rezai-Zadeh, Kavon, Jodry, Dominique, Rentsendorj, Altan, Town, Terrence · 2010 · Journal of Neural Transmission
  18. Neuronal Structure is Altered by Amyloid Plaques
    Tara L. Spires‐Jones, Bradley T. Hyman · 2004 · Reviews in the Neurosciences
  19. A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ
    Elizabeth Head, Viorela Pop, Vitaly Vasilevko, MaryAnn Hill, Tommy Saing, Floyd M. Sarsoza, Michaela Nistor, Lori‐Ann Christie, Saskia C. F. Milton, Charles G. Glabe et al. · 2008 · Journal of Neuroscience
  20. Microglial transplantation increases amyloid‐β clearance in Alzheimer model rats
    Kazuyuki Takata, Yoshihisa Kitamura, Daijiro Yanagisawa, Shigehiro Morikawa, Masahito Morita, Toshiro Inubushi, Daiju Tsuchiya, Saori Chishiro, Mana Saeki, Takashi Taniguchi et al. · 2007 · FEBS Letters
  21. Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials
    Donna M. Wilcock, Carol A. Colton · 2008 · Journal of Alzheimer s Disease
  22. Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease
    Florence Pasquier, Carl Sadowsky, Ann R Holstein, Ghislaine Le Prince, Yahong Peng, Nicholas M. Jackson, Nick C. Fox, Nzeera Ketter, Enchi Liu, J. Michael Ryan et al. · 2016 · Journal of Alzheimer s Disease
  23. Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
    Felix C. Weber, Bernd Bohrmann, Jens Niewoehner, Jens A. A. Fischer, Petra Rueger, Georg Tiefenthaler, Joerg Moelleken, Alexander Bujotzek, Kevin Brady, Thomas Singer et al. · 2018 · Cell Reports
  24. Systemic and Acquired Immune Responses in Alzheimer's Disease
    Markus Britschgi, Tony Wyss‐Coray · 2007 · International review of neurobiology
  25. Microglial alterations in human Alzheimer's disease following Aβ42 immunization
    E. Zotova, Clive Holmes, David Annandale Johnston, James Neal, James A. R. Nicoll, Delphine Boche · 2010 · Neuropathology and Applied Neurobiology
  26. Neurovascular Pathways and Alzheimer Amyloid β-peptide
    Zlokovic, Berislav V., Deane, Rashid, Sallstrom, Jan, Chow, Nienwen, Miano, Joseph M. · 2006 · Brain Pathology
  27. Advances in Alzheimer’s disease’s pharmacological treatment
    Carlos Elias Conti Filho, Lairane Bridi Loss, Clairton Marcolongo Pereira, Joamyr Victor Rossoni, Rafael Mazioli Barcelos, Orlando Chiarelli-Neto, Bruno Spalenza da Silva, Roberta Passamani Ambrósio, Fernanda Cristina de Abreu Quintela Castro, Sarah Fernandes Teixeira et al. · 2023 · Frontiers in Pharmacology
  28. SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain
    Delphine Boche, James A. R. Nicoll · 2008 · Brain Pathology
  29. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-β peptide in vivo
    C-S Hong, William F. Goins, James R. Goss, Edward A. Burton, Joseph C. Glorioso · 2006 · Gene Therapy
  30. Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
    Steven Mark Greenberg, Francesco Bax, Susanne J. van Veluw · 2025 · Nature Reviews Neurology
  31. The Development of Anti-Amyloid Therapy for Alzheimer???s Disease
    Paul S. S. Aisen · 2005 · CNS Drugs
  32. Interactions between inflammation, sex steroids, and Alzheimer’s disease risk factors
    M. F. Uchoa, V. Moser, Christian J. Pike · 2016 · Frontiers in neuroendocrinology (Print)
  33. Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
    Michael Thomas Heneka, David Morgan, Frank Jessen · 2024 · The Lancet
  34. Microglial Activation in Alzheimers Disease
    Johannes C. M. Schlachetzki, Michael Hüll · 2009 · Current Alzheimer Research
  35. Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flow
    Yoon Jung Choi, Sukyung Chae, Jeong Hun Kim, Kate F. Barald, Joong Yull Park, Sang‐Hoon Lee · 2013 · Scientific Reports
  36. Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine — A Novel Immunotherapeutic Strategy
    Nina Movsesyan, Anahit Ghochikyan, Mikayel Mkrtichyan, Irina Petrushina, Hayk Davtyan, Purevdorj Baljinnyam Olkhanud, Elizabeth Head, Arya Biragyn, David H. Cribbs, Michael G. Agadjanyan · 2008 · PLoS ONE
  37. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide
    Paolo Paganetti, Verena Calanca, Carmela Galli, Muriel Stefani, Maurizio Molinari · 2005 · The Journal of Cell Biology
  38. Afferent and efferent immunological pathways of the brain. Anatomy, Function and Failure
    Roxana Octavia Carare, Cheryl A. Hawkes, Roy O. Weller · 2013 · Brain Behavior and Immunity
  39. Active immunotherapy options for Alzheimer’s disease
    Bengt G. Winblad, Ana Graf, Marie‐Emmanuelle Riviere, Niels Andreasen, J. Michael Ryan · 2014 · Alzheimer s Research & Therapy
  40. Immunotherapy for Alzheimer's disease
    Thomas Wısnıewskı, Fernando Goñi · 2014 · Biochemical Pharmacology
  41. Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
    Richard J. Caselli, Amylou Constance Dueck, Dona E.C. Locke, Charlene R. Hoffman‐Snyder, Bryan Keith Woodruff, Steven Z. Rapcsak, Eric M. Reiman · 2011 · Neurology
  42. Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
    Ann D. Cohen, Gil Dan Rabinovici, Chester A. Mathis, William J. Jagust, William Edward Klunk, Miloš D. Ikonomović · 2012 · Advances in pharmacology
  43. Lessons from the AN 1792 Alzheimer vaccine: lest we forget
    Stephen R. Robinson, Glenda M. Bishop, Hyoung‐gon Lee, Gerald W Münch · 2004 · Neurobiology of Aging
  44. Clearance and prevention of prion infection in cell culture by anti‐PrP antibodies
    Joanna E. Pankiewicz, Frances C. Prelli, Man‐Sun Sy, Richard J. Kascsak, Regina B. Kascsak, Daryl S. Spinner, Richard I. Carp, Harry C. Meeker, Martin J. Sadowski, Thomas Wısnıewskı · 2006 · European Journal of Neuroscience
  45. Neuronal histamine and cognitive symptoms in Alzheimer's disease
    Armin Zlomuzica, Dorothea Dere, Sonja Binder, Maria A. de Souza Silva, Joseph P. Huston, Ekrem Dere · 2015 · Neuropharmacology
  46. Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
    Wang, Chang Yi, Finstad, Connie L., Walfield, Alan M., Sia, Charles, Sokoll, Kenneth K., Chang, Tseng-Yuan, Fang, Xin De, Hung, Chung Ho, Hutter-Paier, Birgit, Windisch, Manfred · 2007 · Vaccine
  47. The Aβ Hypothesis: Leading Us to Rationally‐Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease
    Todd E. Golde · 2005 · Brain Pathology
  48. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease
    Ken-ichiro Fukuchi, Kazuki Tahara, Hong‐Duck Kim, J. Adam Maxwell, Terry L. Lewis, Mary Ann Accavitti-Loper, Helen Kim, Selvarangan Ponnazhagan, Robert Lalonde · 2006 · Neurobiology of Disease
  49. ABCA7 Mediates Phagocytic Clearance of Amyloid-β in the Brain
    YuHong Fu, Jen-Hsiang T. Hsiao, George Paxinos, Glenda Margaret Halliday, Woojin Scott Kim · 2016 · Journal of Alzheimer s Disease
  50. Inflammation in transgenic mouse models of neurodegenerative disorders
    Schwab, Claudia, Klegeris, Andis, McGeer, Patrick. L. · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  51. Tau as a Therapeutic Target for Alzheimers Disease
    Allal Boutajangout, Einar M. Sigurdsson, P. K. Krishnamurthy · 2011 · Current Alzheimer Research
  52. Lysosome‐associated membrane protein 1 (LAMP‐1) in Alzheimer’s disease
    Marta Barrachina, Tamara Maes, Carlos Buesa, Isidró Ferrer · 2006 · Neuropathology and Applied Neurobiology
  53. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model
    Jindong Ding, John C. Lin, Brian E. Mace, Rolf Herrmann, Patrick M. Sullivan, Catherine Bowes Rickman · 2007 · Vision Research
  54. Tau Ser262 phosphorylation is critical for A 42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease
    Iijima, K., Gatt, A., Iijima-Ando, K. · 2010 · Human Molecular Genetics
  55. Use of Animal Models of Human Disease for Nonclinical Safety Assessment of Novel Pharmaceuticals
    Sherry J. Morgan, Chandikumar S. Elangbam, Shawn Jay Berens, Evan B. Janovitz, Allison Vitsky, Tanja S. Zabka, Laura A. Conour · 2012 · Toxicologic Pathology
  56. Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound B
    Steven Mark Greenberg, Thomas J. Grabowski, M. Edip Gurol, Maureen E. Skehan, R. N. Kaveer Nandigam, John Alex Becker, Mónica Garcı́a-Alloza, Claudia M. Prada, Matthew P. Frosch, Jonathan M. Rosand et al. · 2008 · Annals of Neurology
  57. Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease
    Weisman, David, Hakimian, Edwin, Ho, Gilbert J. · 2006 · Vitamins & Hormones
  58. Epitomic Characterization of the Specificity of the Anti-Amyloid Aβ Monoclonal Antibodies 6E10 and 4G8
    Baghallab, Ibtisam, Reyes-Ruiz, Jorge Mauricio, Abulnaja, Khalid, Huwait, Etimad, Glabe, Charles · 2018 · Journal of Alzheimer s Disease
  59. Microglia in Alzheimer's Disease: It's All About Context
    Weitz, Tara M., Town, Terrence · 2012 · International Journal of Alzheimer's Disease
  60. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid
    Donna M. Wilcock, Paul T. Jantzen, Qi Li, David Morgan, Marcia N. Gordon · 2006 · Neuroscience
  61. Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrP<sup>Sc</sup>, even upon LPS stimulation
    Hughes, Martina M., Field, Robert H., Perry, V. Hugh, Murray, Carol L., Cunningham, Colm · 2010 · Glia
  62. Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy
    Kozberg, Mariel G, Yi, Irvin, Freeze, Whitney M, Auger, Corinne A, Scherlek, Ashley A, Greenberg, Steven M, van Veluw, Susanne J · 2022 · Brain Communications
  63. Disease-Modifying Therapies in Alzheimer???s Disease
    Michael H ll, Thomas Berger, Michael Thomas Heneka · 2006 · Drugs
  64. Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
    Samir Kumar‐Singh · 2008 · Genes Brain & Behavior
  65. Rational targeting for prion therapeutics
    Giovanna R. Mallucci, John Collinge · 2004 · Nature reviews. Neuroscience
  66. Anti-Aβ1–11 Antibody Binds to Different β-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers
    Grigor Mamikonyan, Mihaela Necula, Mikayel Mkrtichyan, Anahit Ghochikyan, Irina Petrushina, Nina Movsesyan, Erene W. Mina, Anatoly B. Kiyatkin, Charles G. Glabe, David H. Cribbs et al. · 2007 · Journal of Biological Chemistry
  67. Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in T <sub>H</sub> 1 and T <sub>H</sub> 17 Versions of Experimental Autoimmune Encephalomyelitis
    Grant, Jacqueline L., Ghosn, Eliver Eid Bou, Axtell, Robert C., Herges, Katja, Kuipers, Hedwich F., Woodling, Nathan S., Andreasson, Katrin, Herzenberg, Leonard A., Herzenberg, Leonore A., Steinman, Lawrence · 2012 · Science Translational Medicine
  68. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
    Sage Arbor, Mike LaFontaine, Medhane G. Cumbay · 2016 · Europe PMC (PubMed Central)
  69. Intranasal drug delivery for treatment of Alzheimer’s disease
    Leonor Fonseca, João A. Lopes, João Vieira, Cláudia Viegas, Cláudia S. Oliveira, Rafael P. Hartmann, Pedro Fonte · 2021 · Drug Delivery and Translational Research
  70. One Hundred Years after the Discovery of Alzheimer's Disease. A Turning Point for Therapy?
    Ezio Giacobini, Robert E. Becker · 2007 · Journal of Alzheimer s Disease
  71. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease
    J. Steven Jacobsen, Peter H. Reinhart, Menelas N. Pangalos · 2005 · NeuroRx
  72. Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric Aβ Species in Amyloid Precursor Protein Transgenic Mice
    Irina Petrushina, Anahit Ghochikyan, Mikayel Mktrichyan, Gregory Mamikonyan, Nina Movsesyan, Hayk Davtyan, Archita J. Patel, Elizabeth Head, David H. Cribbs, Michael G. Agadjanyan · 2007 · Journal of Neuroscience
  73. Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
    Chakroborty, Shreaya, Stutzmann, Grace E. · 2014 · European Journal of Pharmacology
  74. Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages
    Ayodeji A. Asuni, Allal Boutajangout, Henrieta Scholtzova, Elin Knudsen, Yong Sheng Li, David Quartermain, Blas Frangione, Thomas Wısnıewskı, Einar M. Sigurdsson · 2006 · European Journal of Neuroscience
  75. Amyloid-β Immunotherapy for Alzheimers Disease
    Hongjun Fu, B. Liu, Jeffrey L. Frost, Cynthia Ann Lemere · 2010 · CNS & Neurological Disorders - Drug Targets
  76. The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology
    Maria Laura Giuffrida, Filippo Caraci, Paolo De Bona, G. Pappalardo, Ferdinando Nicoletti, Enrico Rizzarelli, Agata Copani · 2010 · Reviews in the Neurosciences
  77. Amyloid Beta-Related Angiitis—A Case Report and Comprehensive Review of Literature of 94 Cases
    Abhijeet S. Danve, Marjorie R. Grafe, Atul A. Deodhar · 2014 · Seminars in Arthritis and Rheumatism
  78. Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease
    Valentina Echeverrı́a, Alexandre Iarkov, Gjumrakch Aliev · 2016 · Progress in Neurobiology
  79. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
    Agarwal, Amit, Gupta, Vivek, Brahmbhatt, Pavan, Desai, Amit, Vibhute, Prasanna, Joseph-Mathurin, Nelly, Bathla, Girish · 2023 · RadioGraphics
  80. Bapineuzumab
    Geoffrey A. Kerchner, Adam L. Boxer · 2010 · Expert Opinion on Biological Therapy
  81. The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases
    Yi Qiu, Shiyuan Huang, Li Peng, Li Yang, Guosong Zhang, Tao Liu, Fang Yan, Xi Peng · 2025 · MedComm
  82. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease
    Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi, Xiao Xiao, Shin’ichi Takeda, Keikichi Takahashi, Howard L. Weiner, Takeshi Tabira · 2004 · Journal of Alzheimer s Disease
  83. Targeting Aβ and tau in Alzheimer's disease, an early interim report
    Golde, Todd E., Petrucelli, Leonard, Lewis, Jada · 2010 · Experimental Neurology
  84. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques
    Joseph F. Poduslo, Muthu Ramakrishnan, Silvina S. Holasek, Marina Ramı́rez-Alvarado, Karunya K. Kandimalla, Emily J. Gilles, Geoffry L. Curran, Thomas M. Wengenack · 2007 · Journal of Neurochemistry
  85. Inflammation and gliosis in neurological diseases – clinical implications
    Anna Członkowska, Iwona Kurkowska‐Jastrzębska · 2010 · Journal of Neuroimmunology
  86. Yin and Yang: complement activation and regulation in Alzheimer’s disease
    Yong Shen, Seppo Meri · 2003 · Progress in Neurobiology
  87. Targeting microglia for the treatment of Alzheimer’s disease
    Patrick L. McGeer, Edith G. McGeer · 2014 · Expert Opinion on Therapeutic Targets
  88. Emerging Therapeutics for Alzheimer's Disease
    Karen Chiang, Edward H. Koo · 2014 · The Annual Review of Pharmacology and Toxicology
  89. Synaptic dysfunction and oxidative stress in Alzheimer's disease: Emerging mechanisms
    Diego A. Forero, Gemma Casadesús, George L. Perry, Humberto Arboleda · 2006 · Journal of Cellular and Molecular Medicine
  90. Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications
    Jianming, Wu, Ling, Li · 2016 · The Journal of Biomedical Research
  91. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases
    Douglas G. Walker, L-F Lue · 2005 · Journal of Neuroscience Research
  92. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow
    Li, Hongmei, Guo, Qinxi, Inoue, Taeko, Polito, Vinicia A, Tabuchi, Katsuhiko, Hammer, Robert E, Pautler, Robia G, Taffet, George E, Zheng, Hui · 2014 · Molecular Neurodegeneration
  93. Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
    Kasia Lobello, J. Michael Ryan, Enchi Liu, Gregory A. Rippon, Ronald S. Black · 2012 · International Journal of Alzheimer s Disease
  94. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
    David A. Loeffler · 2023 · Journal of Alzheimer s Disease Reports
  95. Amyloid plaque imaging in vivo: current achievement and future prospects
    Agneta K. Nordberg · 2008 · European Journal of Nuclear Medicine and Molecular Imaging
  96. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease
    Boche, Delphine, Donald, Jane, Love, Seth, Harris, Scott, Neal, James W., Holmes, Clive, Nicoll, James A. R. · 2010 · Acta Neuropathologica
  97. Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings
    Andreas Charidimou, Anant Subramanian Krishnan, David John Werring, Hans Rolf Jäger · 2013 · Neuroradiology
  98. Cerebral Amyloid Angiopathy
    2012 · Progress in Molecular Biology and Translational Science
  99. Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report
    Rudolph J. Castellani, Elisheva D. Shanes, Matthew McCord, Nicholas J. Reish, Margaret E. Flanagan, Marsel M. Mesulam, Pouya Jamshidi · 2023 · Journal of Alzheimer s Disease
  100. Up‐regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease
    Ester Angulo-Pueyo, Verónique Noé, Vicent Casadó, Josefa Mallol, Teresa Gómez‐Isla, Carmen Lluís, Isidró Ferrer, Carlos J. Ciudad, Rafael Franco · 2004 · Journal of Neurochemistry